The global Cardiac Resynchronization Therapy (CRT) market size was valued at USD 4.74 billion in 2016 and is expected to grow at a CAGR of 7.9% over the forecast period. The high growth is due to an increased prevalence of cardiovascular disease worldwide. Increasing sedentary lifestyle and increasing smoking habits will increase CRT market growth by increasing cardiovascular disease.
In addition, as the technological advancement of CRT devices increases, the market growth will be further strengthened. Companies like Medtronic and Abbott, for example, are focusing on advances in technology related to cardiac devices. In addition, the increase in government initiatives for the treatment of various cardiovascular diseases will further promote industry growth.
A full report of Cardiac Resynchronization Therapy Market available at https://www.orionmarketreports.com/cardiac-resynchronization-therapy-market/52641/
Cardiac Resynchronization Therapy Market Segmentation
By Product Type
• Cardiac Resynchronization Therapy Defibrillators
• Cardiac Resynchronization Therapy Pacemakers
By End User
• Hospitals & Cardiac Centers
• Ambulatory Surgery Centers
Company Profiles:
• Medtronic, PLC.
• Abbott Laboratories
• Biotronik
• Boston Scientific Corporation
• Microport Scientific Corporation
• Medico S.P.A.
• St. Jude Medical
• LivaNova Plc
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
